GOLD 2026 reframes how long-term COPD control is approached in clinical practice. Beyond spirometry alone, the updated guidance places greater emphasis on sustained symptom control, exacerbation prevention, and preservation of functional capacity—recognizing that airflow limitation and day-to-day disease impact do not always move in parallel.

The 2026 update more clearly distinguishes between initial and follow-up treatment pathways and emphasizes identifying future risk earlier in the disease course. Even a single moderate exacerbation is recognized as a meaningful risk signal, reinforcing a proactive strategy focused on early initiation of maintenance therapy to stabilize disease and reduce future events rather than reacting to repeated exacerbations.

Bronchodilation remains central to COPD management under GOLD 2026. Dual long-acting bronchodilation (LABA + LAMA) is recommended as preferred initial therapy for high-risk Group E, rather than initiating triple therapy. GOLD 2026 does not recommend initiating treatment with triple therapy as routine initial management. Instead, inhaled corticosteroids are added selectively—primarily in patients with blood eosinophil counts ≥300 cells/µL—highlighting that ICS use is conditional and not part of universal initial management. Because many symptomatic patients fall within Groups B and E, sustained dual bronchodilation remains foundational to long-term disease control.

As GOLD 2026 places greater weight on longitudinal assessment across the disease continuum, integrating symptoms, exacerbation history, lung function, and functional capacity into routine follow-up remains essential.

Which GOLD 2026 updates have most influenced how you assess long-term COPD control? Where does long-acting bronchodilation fit into your current approach to maintaining control?